These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Hernández-Perera O; Pérez-Sala D; Navarro-Antolín J; Sánchez-Pascuala R; Hernández G; Díaz C; Lamas S J Clin Invest; 1998 Jun; 101(12):2711-9. PubMed ID: 9637705 [TBL] [Abstract][Full Text] [Related]
18. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Wagner AH; Köhler T; Rückschloss U; Just I; Hecker M Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):61-9. PubMed ID: 10634801 [TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Martínez-González J; Alfón J; Berrozpe M; Badimon L Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203 [TBL] [Abstract][Full Text] [Related]
20. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Parker RA; Huang Q; Tesfamariam B Atherosclerosis; 2003 Jul; 169(1):19-29. PubMed ID: 12860247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]